| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net income | 117,432 | 45,653 |
| Stock-based compensation | 38,900 | 25,720 |
| Amortization of premiums and accretion of discounts on investment securities | 4,754 | 3,652 |
| Amortization of intangible assets | 8,167 | 5,444 |
| Depreciation | 669 | 442 |
| Accounts receivable, net | 17,111 | 8,766 |
| Interest and other receivables | 17,626 | 6,225 |
| Inventory | 13,305 | 14,553 |
| Prepaid expenses | 5,187 | -2,934 |
| Other assets | 2,006 | 1,306 |
| Operating lease right-of-use assets | -6,471 | -4,259 |
| Accounts payable | 5,555 | 3,905 |
| Accrued liabilities | 49,126 | 21,350 |
| Operating lease liabilities | -3,597 | -1,418 |
| Long-term liabilities | -4,167 | 10,492 |
| Net cash provided by operating activities | 158,567 | 84,279 |
| Purchases of investment securities | 534,951 | 330,398 |
| Sale and maturity of investment securities | 387,779 | 262,190 |
| Intangible assets | 98,838 | 98,838 |
| Purchases of property and equipment | 685 | 297 |
| Net cash used in investing activities | -246,695 | -167,343 |
| Proceeds from issuance of common stock, net of issuance costs | 27,217 | 17,794 |
| Net cash provided by financing activities | 27,217 | 17,794 |
| Effect of exchange rate changes on cash | 19 | 19 |
| Net decrease in cash, cash equivalents and restricted cash | -60,892 | -65,251 |
| Cash and cash equivalents at beginning of period | 328,359 | - |
| Cash and cash equivalents at end of period | 267,467 | - |
ACADIA PHARMACEUTICALS INC (ACAD)
ACADIA PHARMACEUTICALS INC (ACAD)